Literature DB >> 25111004

Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.

Taxiarchis V Kourelis1, Shaji K Kumar, Ronald S Go, Prashant Kapoor, Robert A Kyle, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Suzanne R Hayman, Nelson Leung, David Dingli, John A Lust, Yi Lin, Stephen R Zeldenrust, S Vincent Rajkumar, Angela Dispenzieri.   

Abstract

AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25111004     DOI: 10.1002/ajh.23827

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Monoclonal gammopathy of renal significance: systemic involvement by benign condition.

Authors:  Vincenzo L'Imperio; Paolo Fabbrini; Franco Ferrario; Federico Pieruzzi; Antonella Tosoni; Rinaldo Brivio; Enrico Maria Pogliani; Fabio Pagni
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

Review 2.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

3.  A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data from 1,064 Chinese patients.

Authors:  Wei Yan; Yanze Cao; Aijun Liao; Wei Yang; Jian Li; Huihan Wang
Journal:  Ann Transl Med       Date:  2021-08

Review 4.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.